Recent advances of cocktail chemotherapy by combination drug delivery systems

Advanced Drug Delivery Reviews

Volumn 98, Issue , 2016, Pages 19-34

  Hu, Quanyin ^a,b   Sun, Wujin ^a,b   Wang, Chao ^a,b   Gu, Zhen ^a,b,c  

^a Biomedical Research Imaging Center   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; Combination; Drug delivery; Nanocarriers

Indexed keywords

DISEASES; DRUG DELIVERY; PHARMACOKINETICS;

CANCER; CO DELIVERIES; COMBINATION; COMBINATION CHEMOTHERAPY; DRUG DELIVERY STRATEGIES; DRUG DELIVERY SYSTEM; NANO-CARRIERS; SMALL MOLECULES;

CHEMOTHERAPY;

CHLORAMBUCIL; CISPLATIN; COMBRETASTATIN A4; CURCUMIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DISULFIRAM; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GRAPHENE; IDARUBICIN; IRINOTECAN; LIPOSOME; MESOPOROUS SILICA NANOPARTICLE; METHOTREXATE; NANOCAPSULE; NANOCARRIER; OXALIPLATIN; PACLITAXEL; POLYLACTIC ACID; QUERCETIN; RETINOIC ACID; SMALL INTERFERING RNA; TAMOXIFEN; UNINDEXED DRUG; VALRUBICIN; ANTINEOPLASTIC AGENT; NANOPARTICLE;

BLADDER CANCER; BREAST CANCER; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ENCAPSULATION; HUMAN; LIVER CANCER; MELANOMA; MICELLE; NANOTECHNOLOGY; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; REVIEW; UTERINE CERVIX CANCER; ANIMAL; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84960405256     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.022     Document Type: Review

References (194)

1. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
2. Stewart B.W., Kleihues P., I.A.f.R.o. Cancer. World Cancer Report 2003, IARC Press, Lyon.
3. I.A.f.R.o. Cancer. World Cancer Report 2014 2014, WHO, Geneva.
4. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
5. DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L., Alteri R., Robbins A.S., Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 2014, 64:252-271.
6. Ward E., DeSantis C., Robbins A., Kohler B., Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:83-103.
7. Sporn M.B. The war on cancer. Lancet 1996, 347:1377-1381.
8. DePinho R.A. The age of cancer. Nature 2000, 408:248-254.
9. Chabner B.A., Roberts T.G. Chemotherapy and the war on cancer. Nat. Rev. Cancer 2005, 5:65-72.
10. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat. Rev. Cancer 2007, 7:192-201.
11. Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., De Lena M., Tancini G., Bajetta E., Musumeci R. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 1976, 294:405-410.
12. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
13. Coffey J.C., Wang J., Smith M., Bouchier-Hayes D., Cotter T., Redmond H. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol. 2003, 4:760-768.
14. Pardoll D., Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat. Med. 2004, 10:887-892.
15. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
16. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
17. Heldin C.-H., Rubin K., Pietras K., Östman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
18. Finkel T., Serrano M., Blasco M.A. The common biology of cancer and ageing. Nature 2007, 448:767-774.
19. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
20. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009, 6:465-477.
21. Lotfi-Jam K., Carey M., Jefford M., Schofield P., Charleson C., Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J. Clin. Oncol. 2008, 26:5618-5629.
22. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
23. Falleti M.G., Sanfilippo A., Maruff P., Weih L., Phillips K.-A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005, 59:60-70.
24. Kamb A., Wee S., Lengauer C. Why is cancer drug discovery so difficult?. Nat. Rev. Drug Discov. 2007, 6:115-120.
25. Klastersky J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr. Opin. Oncol. 2006, 18:316-320.
26. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
27. Lavan D.A., McGuire T., Langer R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 2003, 21:1184-1191.
28. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
29. Saltzman W.M., Olbricht W.L. Building drug delivery into tissue engineering design. Nat. Rev. Drug Discov. 2002, 1:177-186.
30. Langer R. Drug delivery and targeting. Nature 1998, 392:5-10.
31. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
32. Goldberg M., Langer R., Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J. Biomater. Sci. Polym. Ed. 2007, 18:241-268.
33. Pillai O., Panchagnula R. Polymers in drug delivery. Curr. Opin. Chem. Biol. 2001, 5:447-451.
34. Shim M.S., Kwon Y.J. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv. Drug Deliv. Rev. 2012, 64:1046-1059.
35. Wissing S., Kayser O., Müller R. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
36. Lian T., Ho R.J. Trends and developments in liposome drug delivery systems. J. Pharm. Sci. 2001, 90:667-680.
37. Samad A., Sultana Y., Aqil M. Liposomal drug delivery systems: an update review. Curr. Drug Deliv. 2007, 4:297-305.
38. Mo R., Jiang T., Gu Z. Recent progress in multidrug delivery to cancer cells by liposomes. Nanomedicine 2014, 9:1117-1120.
39. Dong Y., Eltoukhy A.A., Alabi C.A., Khan O.F., Veiseh O., Dorkin J.R., Sirirungruang S., Yin H., Tang B.C., Pelet J.M. Lipid-like nanomaterials for simultaneous gene expression and silencing in vivo. Adv. Healthcare Mater. 2014, 3:1392-1397.
40. Liong M., Lu J., Kovochich M., Xia T., Ruehm S.G., Nel A.E., Tamanoi F., Zink J.I. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008, 2:889-896.
41. Arruebo M., Fernández-Pacheco R., Ibarra M.R., Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today 2007, 2:22-32.
42. Arruebo M. Drug delivery from structured porous inorganic materials. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2012, 4:16-30.
43. Sun C., Lee J.S., Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 2008, 60:1252-1265.
44. Sun W., Jiang T., Lu Y., Reiff M., Mo R., Gu Z. Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J. Am. Chem. Soc. 2014, 136:14722-14725.
45. Andersen E.S., Dong M., Nielsen M.M., Jahn K., Subramani R., Mamdouh W., Golas M.M., Sander B., Stark H., Oliveira C.L. Self-assembly of a nanoscale DNA box with a controllable lid. Nature 2009, 459:73-76.
46. Lee H., Lytton-Jean A.K., Chen Y., Love K.T., Park A.I., Karagiannis E.D., Sehgal A., Querbes W., Zurenko C.S., Jayaraman M. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 2012, 7:389-393.
47. Rothemund P.W. Folding DNA to create nanoscale shapes and patterns. Nature 2006, 440:297-302.
48. Sun W., Gu Z. Engineering DNA scaffolds for delivery of anticancer therapeutics. Biomater. Sci. 2015, 3:1018-1024.
49. Sun W., Lu Y., Gu Z. Advances in anticancer protein delivery using micro-/nanoparticles. Part. Part. Syst. Charact. 2014, 31:1204-1222.
50. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
51. Shi J., Votruba A.R., Farokhzad O.C., Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 2010, 10:3223-3230.
52. Sarikaya M., Tamerler C., Jen A.K.-Y., Schulten K., Baneyx F. Molecular biomimetics: nanotechnology through biology. Nat. Mater. 2003, 2:577-585.
53. Wagner V., Dullaart A., Bock A.-K., Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24:1211-1217.
54. Smith D.M., Simon J.K., Baker J.R. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 2013, 13:592-605.
55. Liu D., Bimbo L.M., Mäkilä E., Villanova F., Kaasalainen M., Herranz-Blanco B., Caramella C.M., Lehto V.-P., Salonen J., Herzig K.-H. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J. Control. Release 2013, 170:268-278.
56. Zhang L., Radovic-Moreno A.F., Alexis F., Gu F.X., Basto P.A., Bagalkot V., Jon S., Langer R.S., Farokhzad O.C. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007, 2:1268-1271.
57. Guo S., Huang L. Nanoparticles containing insoluble drug for cancer therapy. Biotechnol. Adv. 2014, 32:778-788.
58. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
59. Yoo J.-W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 2010, 16:2298-2307.
60. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
61. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
62. Li S.-D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control. Release 2010, 145:178-181.
63. Li S.-D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5:496-504.
64. Medina C., Santos-Martinez M., Radomski A., Corrigan O., Radomski M. Nanoparticles: pharmacological and toxicological significance. Br. J. Pharmacol. 2007, 150:552-558.
65. Hu Q., Katti P.S., Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale 2014, 6:12273-12286.
66. Lu Y., Sun W., Gu Z. Stimuli-responsive nanomaterials for therapeutic protein delivery. J. Control. Release 2014, 194:1-19.
67. Davis M.E., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
68. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9:615-627.
69. Minchin R. Nanomedicine: sizing up targets with nanoparticles. Nat. Nanotechnol. 2008, 3:12-13.
70. Sanhai W.R., Sakamoto J.H., Canady R., Ferrari M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3:242-244.
71. Albanese A., Tang P.S., Chan W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 2012, 14:1-16.
72. Song X.R., Cai Z., Zheng Y., He G., Cui F.Y., Gong D.Q., Hou S.X., Xiong S.J., Lei X.J., Wei Y.Q. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 2009, 37:300-305.
73. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., Langer R., Farokhzad O.C. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17939-17944.
74. Batist G., Gelmon K.A., Chi K.N., Miller W.H., Chia S.K., Mayer L.D., Swenson C.E., Janoff A.S., Louie A.C. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:692-700.
75. Feldman E.J., Lancet J.E., Kolitz J.E., Ritchie E.K., Roboz G.J., List A.F., Allen S.L., Asatiani E., Mayer L.D., Swenson C. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5: 1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 2011, 29:979-985.
76. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31:3694-3706.
77. Jia L., Li Z., Shen J., Zheng D., Tian X., Guo H., Chang P. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance. Int. J. Pharm. 2015, 489:318-330.
78. Gerber H.-P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005, 65:671-680.
79. Ibrahim N., Yu Y., Walsh W.R., Yang J.-L. Molecular targeted therapies for cancer: Sorafenib monotherapy and its combination with other therapies (review). Oncol. Rep. 2012, 27:1303-1311.
80. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 2009, 61:1203-1213.
81. Dai X., Tan C. Combination of microRNA therapeutics with small-molecule anticancer drugs: mechanism of action and co-delivery nanocarriers. Adv. Drug Deliv. Rev. 2015, 81:184-197.
82. Xu X., Ho W., Zhang X., Bertrand N., Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol. Med. 2015, 21:223-232.
83. Pacardo D.B., Ligler F.S., Gu Z. Programmable nanomedicine: synergistic and sequential drug delivery systems. Nanoscale 2015, 7:3381-3391.
84. Bang Y.-J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
85. Bozic I., Reiter J.G., Allen B., Antal T., Chatterjee K., Shah P., Moon Y.S., Yaqubie A., Kelly N., Le D.T. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013, 2:e00747.
86. Carrick S., Parker S., Thornton C.E., Ghersi D., Simes J., Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst. Rev. 2009, CD003372.
87. Hu C.-M.J., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 2010, 1:323-334.
88. Hu C.-M.J., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83:1104-1111.
89. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer 2002, 2:143-148.
90. Papac R.J. Origins of cancer therapy. Yale J. Biol. Med. 2001, 74:391.
91. Farber S., Diamond L.K., Mercer R.D., Sylvester R.F., Wolff J.A. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N. Engl. J. Med. 1948, 238:787-793.
92. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
93. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
94. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
95. Miao L., Huang L. Exploring the tumor microenvironment with nanoparticles. Nanotechnology-based Precision Tools for the Detection and Treatment of Cancer 2015, 193-226. Springer.
96. Pilpel Y., Sudarsanam P., Church G.M. Identifying regulatory networks by combinatorial analysis of promoter elements. Nat. Genet. 2001, 29:153-159.
97. Müller R. Crosstalk of oncogenic and prostanoid signaling pathways. J. Cancer Res. Clin. Oncol. 2004, 130:429-444.
98. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
99. Kassouf W., Dinney C.P., Brown G., McConkey D.J., Diehl A.J., Bar-Eli M., Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005, 65:10524-10535.
100. Mayer L.D., Janoff A.S. Optimizing combination chemotherapy by controlling drug ratios. Mol. Interv. 2007, 7:216.
101. Jia J., Zhu F., Ma X., Cao Z.W., Li Y.X., Chen Y.Z. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 2009, 8:111-128.
102. MacDonald D., Perry M. The chemotherapy source book. The Chemotherapy Source Book 1992.
103. Tanabe M., Ito Y., Tokudome N., Sugihara T., Miura H., Takahashi S., Seto Y., Iwase T., Hatake K. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer 2009, 16:301-306.
104. Maciejczyk A., Lacko A., Ekiert M., Jagoda E., Wysocka T., Matkowski R., Halon A., Gyorffy B., Lage H., Surowiak P. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. Histol. Histopathol. 2013, 28:513-524.
105. Stillwell T.J., Benson R.C. Cyclophosphamide-induced hemorrhagic cystitis: a review of 100 patients. Cancer 1988, 61:451-457.
106. Goette D.K. Topical chemotherapy with 5-fluorouracil: a review. J. Am. Acad. Dermatol. 1981, 4:633-649.
107. Socinski M.A., Bondarenko I., Karaseva N.A., Makhson A.M., Vynnychenko I., Okamoto I., Hon J.K., Hirsh V., Bhar P., Zhang H. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J. Clin. Oncol. 2012, 30:2055-2062.
108. Belani C.P., Ramalingam S., Perry M.C., LaRocca R.V., Rinaldi D., Gable P.S., Tester W.J. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J. Clin. Oncol. 2008, 26:468-473.
109. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., Mannel R.S., DeGeest K., Hartenbach E.M., Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003, 21:3194-3200.
110. Sun S., Tang L., Zhang J., Lv F., Wang Z., Wang L., Zhang Q., Zheng C., Qiu L., Jia Z. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int. J. Nanomedicine 2014, 9:1443.
111. Honecker F., Kollmannsberger C., Quietzsch D., Haag C., Schroeder M., Spott C., Hartmann J., Baronius W., Hempel V., Kanz L. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anti-Cancer Drugs 2002, 13:497-503.
112. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., Milanowski J., Karnicka-Mlodkowski H., Pesek M., Serwatowski P. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007, 25:1545-1552.
113. Wendel H.-G., de Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
114. Aryal S., Hu C.-M.J., Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharm. 2011, 8:1401-1407.
115. Lammers T., Subr V., Ulbrich K., Peschke P., Huber P.E., Hennink W.E., Storm G. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 2009, 30:3466-3475.
116. Kitano H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 2007, 5:202-210.
117. Bell A. Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiol. Lett. 2005, 253:171-184.
118. Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
119. Berenbaum M. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin. Exp. Immunol. 1977, 28:1.
120. Tacar O., Sriamornsak P., Dass C.R. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 2013, 65:157-170.
121. Gabizon A., Shmeeda H., Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur. J. Pharm. Sci. 2012, 45:388-398.
122. Ganz W., Sridhar K., Ganz S., Gonzalez R., Chakko S., Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996, 53:461-470.
123. Saltiel E., McGuire W. Doxorubicin (adriamycin) cardiomyopathy-a critical review. West. J. Med. 1983, 139:332.
124. Lv S., Tang Z., Li M., Lin J., Song W., Liu H., Huang Y., Zhang Y., Chen X. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 2014, 35:6118-6129.
125. Wang H., Zhao Y., Wu Y., Hu Y.-l., Nan K., Nie G., Chen H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32:8281-8290.
126. Sun R., Liu Y., Li S.-Y., Shen S., Du X.-J., Xu C.-F., Cao Z.-T., Bao Y., Zhu Y.-H., Li Y.-P. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 2015, 37:405-414.
127. Sengupta S., Eavarone D., Capila I., Zhao G., Watson N., Kiziltepe T., Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
128. Marupudi N.I., Han J.E., Li K.W., Renard V.M., Tyler B.M., Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin. Drug Saf. 2007, 6:609-621.
129. Ma P., Mumper R.J. Paclitaxel nano-delivery systems: a comprehensive review. J. Nanomed. Nanotechnol. 2013, 4:1000164.
130. Blagosklonny M.V., Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer 1999, 83:151-156.
131. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem. Pharmacol. 1999, 57:1215-1221.
132. Wood A.J., Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N. Engl. J. Med. 1995, 332:1004-1014.
133. Horwitz S. Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 1993, 5:S3-S6.
134. Cragg G.M. Paclitaxel (Taxol®): a success story with valuable lessons for natural product drug discovery and development. Med. Res. Rev. 1998, 18:315-331.
135. Rowinsky E., Chaudhry V., Cornblath D., Donehower R. Neurotoxicity of taxol. J. Natl. Cancer Inst. Monogr. 1992, 107-115.
136. Guchelaar H.-J., Ten Napel C., De Vries E., Mulder N. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin. Oncol. 1994, 6:40-48.
137. Aryal S., Hu C.M.J., Zhang L. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 2010, 6:1442-1448.
138. Wang W., Song H., Zhang J., Li P., Li C., Wang C., Kong D., Zhao Q. An injectable, thermosensitive and multicompartment hydrogel for simultaneous encapsulation and independent release of a drug cocktail as an effective combination therapy platform. J. Control. Release 2015, 203:57-66.
139. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
140. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet. Comp. Oncol. 2008, 6:1-18.
141. Desale S.S., Cohen S.M., Zhao Y., Kabanov A.V., Bronich T.K. Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. J. Control. Release 2013, 171:339-348.
142. Xiao H., Song H., Yang Q., Cai H., Qi R., Yan L., Liu S., Zheng Y., Huang Y., Liu T. A prodrug strategy to deliver cisplatin (IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials 2012, 33:6507-6519.
143. Cai L., Xu G., Shi C., Guo D., Wang X., Luo J. Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials 2015, 37:456-468.
144. Dingle B.H., Rumble R.B., Brouwers M.C. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can. J. Gastroenterol. 2005, 19:711-716.
145. Aapro M.S., Martin C., Hatty S. Gemcitabine-a safety review. Anti-Cancer Drugs 1998, 9:191-202.
146. Meng H., Wang M., Liu H., Liu X., Situ A., Wu B., Ji Z., Chang C.H., Nel A.E. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano 2015, 9:3540-3557.
147. Huang P., Wang D., Su Y., Huang W., Zhou Y., Cui D., Zhu X., Yan D. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy. J. Am. Chem. Soc. 2014, 136:11748-11756.
148. Ramesh M., Ahlawat P., Srinivas N.R. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed. Chromatogr. 2010, 24:104-123.
149. Steinberg A.D. Chlorambucil in the treatment of patients with immune-mediated rheumatic diseases. Arthritis Rheum. 1993, 36:325-328.
150. Jain A.K., Thanki K., Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol. Pharm. 2013, 10:3459-3474.
151. Jordan V.C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2003, 2:205-213.
152. Cho S.K., Pedram A., Levin E.R., Kwon Y.J. Acid-degradable core-shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD). Biomaterials 2013, 34:10228-10237.
153. Granado-Serrano A.B., Martín M.A., Bravo L., Goya L., Ramos S. Quercetin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J. Nutr. 2006, 136:2715-2721.
154. Mills E.J., Thorlund K., Ioannidis J.P. Calculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapies. J. Clin. Epidemiol. 2012, 65:1282-1288.
155. Touma S.E., Goldberg J.S., Moench P., Guo X., Tickoo S.K., Gudas L.J., Nanus D.M. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin. Cancer Res. 2005, 11:3558-3566.
156. Li M., Tang Z., Lv S., Song W., Hong H., Jing X., Zhang Y., Chen X. Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin. Biomaterials 2014, 35:3851-3864.
157. Gately D., Howell S. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer 1993, 67:1171.
158. Hurley L.H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:188-200.
159. Görlich D. Transport into and out of the cell nucleus. EMBO J. 1998, 17:2721-2727.
160. Robertson J.D., Orrenius S., Zhivotovsky B. Review: nuclear events in apoptosis. J. Struct. Biol. 2000, 129:346-358.
161. Zhong J., Li L., Zhu X., Guan S., Yang Q., Zhou Z., Zhang Z., Huang Y. A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery. Biomaterials 2015, 65:43-55.
162. Lee S.-M., O'Halloran T.V., Nguyen S.T. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J. Am. Chem. Soc. 2010, 132:17130-17138.
163. Bae Y., Diezi T.A., Zhao A., Kwon G.S. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release 2007, 122:324-330.
164. Chen Y., Gao Y., Chen H., Zeng D., Li Y., Zheng Y., Li F., Ji X., Wang X., Chen F. Engineering inorganic nanoemulsions/nanoliposomes by fluoride-silica chemistry for efficient delivery/co-delivery of hydrophobic agents. Adv. Funct. Mater. 2012, 22:1586-1597.
165. Tai W., Mo R., Lu Y., Jiang T., Gu Z. Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. Biomaterials 2014, 35:7194-7203.
166. Miao L., Guo S., Zhang J., Kim W.Y., Huang L. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv. Funct. Mater. 2014, 24:6601-6611.
167. Chou T.-C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 1984, 22:27-55.
168. Ashley C.E., Carnes E.C., Phillips G.K., Padilla D., Durfee P.N., Brown P.A., Hanna T.N., Liu J., Phillips B., Carter M.B. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 2011, 10:389-397.
169. Li F., Zhao X., Wang H., Zhao R., Ji T., Ren H., Anderson G.J., Nie G., Hao J. Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models. Adv. Funct. Mater. 2015, 25:788-798.
170. Liao L., Liu J., Dreaden E.C., Morton S.W., Shopsowitz K.E., Hammond P.T., Johnson J.A. A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J. Am. Chem. Soc. 2014, 136:5896-5899.
171. Barui S., Saha S., Mondal G., Haseena S., Chaudhuri A. Simultaneous delivery of doxorubicin and curcumin encapsulated in liposomes of pegylated RGDK-lipopeptide to tumor vasculature. Biomaterials 2014, 35:1643-1656.
172. Bar-Sela G., Epelbaum R., Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem. 2010, 17:190-197.
173. Wilken R., Veena M.S., Wang M.B., Srivatsan E.S. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 2011, 10:1-19.
174. Duan X., Xiao J., Yin Q., Zhang Z., Yu H., Mao S., Li Y. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013, 7:5858-5869.
175. Loo T.W., Clarke D.M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl. Cancer Inst. 2000, 92:898-902.
176. Loo T.W., Bartlett M.C., Clarke D.M. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol. Pharm. 2004, 1:426-433.
177. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
178. Nielsen D., Skovsgaard T. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim. Biophys. Acta 1992, 1139:169-183.
179. Dorsett Y., Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 2004, 3:318-329.
180. Li J., Wang Y., Zhu Y., Oupický D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J. Control. Release 2013, 172:589-600.
181. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., Wang X., Zhao Y., Ji Z., Zink J.I. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013, 7:994-1005.
182. Xiong X.-B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011, 5:5202-5213.
183. Xu X., Xie K., Zhang X.-Q., Pridgen E.M., Park G.Y., Cui D.S., Shi J., Wu J., Kantoff P.W., Lippard S.J. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:18638-18643.
184. Morton S.W., Lee M.J., Deng Z.J., Dreaden E.C., Siouve E., Shopsowitz K.E., Shah N.J., Yaffe M.B., Hammond P.T. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal. 2014, 7:ra44.
185. Fang R.H., Zhang L. Combinatorial nanotherapeutics: rewiring, then killing, cancer cells. Sci. Signal. 2014, 7:pe13-pe13.
186. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L., Makhson A.N., Cortes J., Lortholary A., Bischoff J. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J. Clin. Oncol. 2012, 30:921-929.
187. Gradishar W.J., Meza L.A., Amin B., Samid D., Hill T., Chen Y.-M., Lower E.E., Marcom P.K. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J. Clin. Oncol. 2004, 22:2321-2327.
188. Lehár J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., Rickles R.J., Short Iii G.F., Staunton J.E., Jin X. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27:659-666.
189. Jiang T., Mo R., Bellotti A., Zhou J., Gu Z. Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv. Funct. Mater. 2014, 24:2295-2304.
190. Jiang T., Sun W., Zhu Q., Burns N.A., Khan S.A., Mo R., Gu Z. Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene. Adv. Mater. 2015, 27:1021-1028.
191. Hu Q., Sun W., Qian C., Wang C., Bomba H.N., Gu Z. Anticancer platelet-mimicking nanovehicles. Adv. Mater. 2015, 10.1002/adma.201503323.
192. Noh J., Kwon B., Han E., Park M., Yang W., Cho W., Yoo W., Khang G., Lee D. Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death. Nat. Commun. 2015, 6:6907.
193. Setyawati M.I., Tay C.Y., Docter D., Stauber R.H., Leong D.T. Understanding and exploiting nanoparticles' intimacy with the blood vessel and blood. Chem. Soc. Rev. 2015, 44:8174-8199.
194. Mitragotri S., Anderson D.G., Chen X., Chow E.K., Ho D., Kabanov A.V., Karp J.M., Kataoka K., Mirkin C.A., Petrosko S.H. Accelerating the translation of nanomaterials in biomedicine. ACS Nano 2015, 9:6644-6654.